Sigma Pharmaceutical Limited
(ASX:SIP) has generated a first half net profit of $16.3 million despite difficult trading conditions and flat growth in the Pharmaceutical Benefits Scheme.
The result marked a 37 per cent drop in the six months ended July 31, 2013, compared with $26.1 million in the previous corresponding period.
Sales revenue rose 3.1 per cent to $1.46 billion.
Sigma says it continues to operate in a challenging environment but will look to the new Federal Government to provide greater certainty in the sector.
The group declared an interim dividend of two cents per share, fully franked.
